Abdominal Center, Nephrology, Helsinki University Hospital, Helsinki, Finland; Folkhälsan Institute of Genetics, Folkhälsan Research Center, Helsinki, Finland.
Department of Oral and Maxillofacial Diseases, Head and Neck Center, Helsinki University Hospital, Helsinki, Finland.
Transplant Proc. 2020 Dec;52(10):3231-3235. doi: 10.1016/j.transproceed.2020.07.007. Epub 2020 Aug 4.
Triggering receptors expressed on myeloid cells (TREMs) and their ligand, peptidoglycan recognition protein 1 (PGLYRP-1), have been detected in secretions from patients with inflammatory diseases, which may lead to the formation of atherosclerotic plaques. Here, we aimed to analyze the association between salivary concentrations of soluble (s)TREM-1 and PGLYRP-1 with death and cardiovascular disease before and after kidney transplantation.
Saliva samples from 53 patients on dialysis were collected during their regular dental evaluation before treatment and after kidney transplantation. Oral inflammatory burden was assessed from panoramic radiographs and full-mouth dental examination. Demographic data, graft function, patient survival, and history of major cardiovascular events (MACEs) were retrieved from hospital records.
Salivary sTREM-1 before transplantation increased the odds for death and MACE. In addition, PGLYRP-1 increased the odds for MACE before transplantation. After transplantation, neither salivary sTREM-1 nor PGLYRP-1 increased the odds for death or MACE, probably because of the previous eradication of oral inflammatory foci. None of the studied biomarkers correlated with kidney transplant function.
Salivary sTREM-1 and PGLYRP-1 before transplantation were associated with MACE and death. The utility of salivary proinflammatory biomarkers for risk stratification in kidney transplant candidates requires further investigation.
在炎症性疾病患者的分泌物中检测到触发髓样细胞表达的受体（TREMs）及其配体肽聚糖识别蛋白 1（PGLYRP-1），这可能导致动脉粥样硬化斑块的形成。在此，我们旨在分析唾液可溶性（s）TREM-1 和 PGLYRP-1 浓度与肾移植前后死亡和心血管疾病的相关性。
在治疗前和肾移植后，对正在接受透析的 53 名患者的唾液样本进行了收集，该样本来自他们定期的牙科评估。从全景片和全口牙科检查评估口腔炎症负担。从医院记录中检索人口统计学数据、移植物功能、患者存活率和主要心血管事件（MACE）病史。
移植前唾液 sTREM-1 增加了死亡和 MACE 的几率。此外，移植前 PGLYRP-1 增加了 MACE 的几率。移植后，唾液 sTREM-1 和 PGLYRP-1 均未增加死亡或 MACE 的几率，这可能是因为先前已消除了口腔炎症病灶。研究中没有任何生物标志物与肾移植功能相关。
移植前唾液 sTREM-1 和 PGLYRP-1 与 MACE 和死亡相关。唾液促炎生物标志物在肾移植候选者中的风险分层中的作用需要进一步研究。
